By Franz Wiesbauer, MD, MPH - 18th Mar 2020 - Blog

Medmastery Group Subscriptions for the Frontliners Fighting Against COVID-19

Physicians and medical professionals from all over the world are united in the fight against the COVID-19 pandemic. Here at Medmastery, we are thankful to our community for all of your efforts in containing the virus and treating your patients. We hope we can support you in this challenging time.

We have decided to make a Medmastery Group Subscription available to every institution that is, or will be, taking care of patients with COVID-19. Every department can apply for a group subscription, free-of-charge, which will give you and up to 20 of your colleagues access to all of our courses.

Who can apply: Department Heads, Residency Directors, Attending Physicians working at hospitals that are, or will be, taking care of COVID-19 patients.

How to apply: Please apply for the group subscription by filling out this form. If you are a staff member, we kindly ask you to share this message with your supervisor.

We will do our best to answer your inquiries as soon as possible. If you have any questions, please contact our customer support at [email protected].

❤️ Thank you for making sacrifices and for everything you do for your local community.

Medmastery COVID-19 Resource Guide

NOTE: Information is changing rapidly, thus each of these resources will need to be reviewed frequently to remain up to date on accurate information. Medmastery is not responsible for the accuracy of this information, but we have found these resources invaluable.

Virus Locator

Live numbers, charts, graphs, and maps to provide an efficient way to follow the progression of COVID-19 and help you discuss information with your colleagues and patients.

Resources and Literature

Accurate information, easy to use algorithms, and go-to guides to aid in your care of patients.

Reliable Social Media

Educational discussion about current challenges, suggestions, and progression of pandemic.

People and institutions to follow on Twitter (our favorite sources):